Promising Atopic Dermatitis Treatment

Topical JAK inhibitors are becoming a major significant force in atopic dermatitis space. Atopic dermatitis or eczema is an inflammatory, non-contagious, chronic skin disorder.

A major force in the atopic dermatitis (AD) space is Topical Janus kinase (JAK) inhibitors. Recently, an increasing number of JAK agents are filling the early and late-stage pipeline.

Ramla Salad, Pharma Analyst at Global Data, comments “JAK inhibitors can combat AD at the immune system level due to their broad inhibitory effect. They are being developed in both oral and topical formulations, which target both mild-to-moderate and moderate-to-severe respectively”.

Atopic Dermatitis / Eczema - Causes - Symptoms - Diagnosis - Treatment - FAQs
Atopic dermatitis is an inflammatory, non-contagious, chronic skin disorder that involves scaly and itchy rashes. It is also called eczema, dermatitis or atopy.

‘Topical JAK inhibitors drugs are progressing as main asset in the array of atopic dermatitis treatment.’

Thus, targeting an array of patient groups to tolerate the topical agents for mild-to-moderate cases can lead to better compliance. Though a relatively small amount of JAKs on the market now, they are set to revolutionize the AD space.

Incyte’s ruxolitinib is a JAK1/2 inhibitor with strong efficacy that targets new patient pool before receiving approval is already marketed as Jakafi, an oral formulation for the treatment of myelofibrosis.

The company is anticipating approval in adults after successful clinical trials in children and is looking to greatly expand its market. Rival Pfizer used a similar tactic with its topical PDE4 inhibitor, Eucrisa (crisaborole).

Powerful New Eczema Drug Approved by FDA
The United States Food and Drug Administration has recently approved Dupilumab injection for treating moderate-to-severe eczema.

LEO Pharma’s delgocitinib is a topical pan-JAK inhibitor used in chronic hand eczema. It is also Ruxolitinib’s closest competitor with fast Track Designation (FTD) that will help to expedite the regulatory process. It is marketed in Japan under the name Corectim for adults and more recently for pediatric patients with AD.

Aclaris Therapeutics’ ATI-1777 is an emollient spray administration that differentiates it from other competitors in CHE treatment.

Study Explains How Allergens Get on Our Nerves
The way in which the immune system interacts with sensory neurons to regulate inflammatory processes in atopic dermatitis has been discovered by scientists.

The remaining topical JAK inhibitor agents like Arcutis Biotherapeutics’ARQ-252 and Novartis’ pan-JAK inhibitor, CEE321 are in the pipeline for AD in the early stage of development show unique promise.

Wearable pH Watch: Your Sweat can Tell a Lot About Your Health
Dehydrated or at risk of skin infections such as dermatitis and acne? Don't worry, relax, a newly developed wearable sensor (pH Watch) can tell a lot about your health from your sweat.

Source-Medindia